共 50 条
- [31] Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial (vol 8, pg e397, 2021)[J]. LANCET HIV, 2021, 8 (12): : E734 - E734Ogbuagu, O.Ruane, P. J.Podzamczer, D.
- [32] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (vol 379, pg 2439, 2012)[J]. LANCET, 2012, 380 (9843): : 730 - 730Sax, P. E.DeJesus, E.Mills, A.
- [33] A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 ( ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial (vol 9, pg e79, 2022)[J]. LANCET HIV, 2022, 9 (12): : E822 - E822Landman, R.De Truchis, P.Assoumou, L.
- [34] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial (vol 282, pg 637, 1999)[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (22): : 2124 - 2124Ettinger, B
- [35] Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial[J]. LANCET HIV, 2019, 6 (06): : E355 - E363Wohl, David A.Yazdanpanah, YazdanBaumgarten, AxelClarke, AmandaThompson, Melanie A.Brinson, CynthiaHagins, DebbieRamgopal, Moti N.Antinori, AndreaWei, XuelianAcosta, RimaCollins, Sean E.Brainard, DianaMartin, Hal
- [36] Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial (vol 5, pg 864, 2017)[J]. LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (12): : E8 - E8Dandona, P.Mathieu, C.Phillip, M.
- [37] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial (vol 16, pg 274, 2015)[J]. LANCET ONCOLOGY, 2015, 16 (03): : E105 - E105Aluwini, S.Pos, F.Schimmel, E.
- [38] Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial (vol 11, pg 171, 2011)[J]. LANCET INFECTIOUS DISEASES, 2011, 11 (03): : 159 - 159Read, Jennifer
- [39] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial (vol 5, pg e545, 2018)[J]. LANCET HIV, 2018, 5 (10): : E545 - E545Molina, J-MWard, D.Brar, I
- [40] Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial[J]. LANCET HIV, 2020, 7 (10): : E666 - E676Venter, Willem D. F.Sokhela, SimisoSimmons, BryonyMoorhouse, MichelleFairlie, LeeMashabane, NkuliSerenata, CeliciaAkpomiemie, GodspowerMasenya, MaseboleQavi, AmbarChandiwana, NomathembaMcCann, KaitlynNorris, ShaneChersich, MatthewMaartens, GaryLalla-Edward, SamantaVos, AlindaClayden, PollyAbrams, ElaineArulappan, NatashaHill, Andrew